Moma Therapeutics, Inc. is a young biotechnlology company based in Boston. Moma is developing matrix-based monocyte cell therapies for the delivery of angiogenic vascular growth factors for treatment of conditions associated with poor circulation and vascular failure.
Moma was founded and is managed by:
Daniel Katzman, MSc, CEO
Daniel brings extensive managerial and entrepreneurial experience in the life sciences industry. Daniel has founded NeuroHealing Pharmaceuticals, where he was responsible for establishing the management team, advisory board, raising capital, obtaining orphan drug designation, patents, INDs and advancing two clinical programs into phase II studies. Daniel has 5 issued patents and over 10 patent applications. Previously, Daniel served as a VP, Business Development, for Oridion Medical (SWX: ORDN) where he conducted the pivotal phase III studies and obtained FDA approval for a drug/device combination (NDA and 510k).
Shai Schubert, PhD, President and CSO
Shai is the inventor of Moma's platform technology and brings extensive hands-on experience in matrix based cell therapy. Shai completed his postdoctoral training at the Harvard-MIT Division of Health Sciences & Technology Biomedical Engineering Center focusing on novel aspects of monocyte function in vascular physiology. Shai received his PhD in Biotechnology from the Technion-Israel Institute of Technology, specializing in vascular cell signaling. Recently, Shai served as a scientist in Pervasis Therapeutics, a cell based therapy startup, where he was responsible for developing new target studies. Shai published in the fields of biochemistry vascular biology and cancer biology as well as 4 patent applications. Previously, Shai co-founded Lucid Biotechnology Ltd, which developed natural anti-inflammatory agents.